On May 18, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, reported that the company will participate in the upcoming Cowen 2nd Annual Virtual Oncology Innovation Summit (Press release, Revolution Medicines, MAY 18, 2021, View Source [SID1234580193]). Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

Cowen 2nd Annual Virtual Oncology Innovation Summit
Conference Date: May 20-21, 2021
Fireside Chat Time/Date: 12:40 p.m. Eastern on Friday, May 21, 2021
Format: Virtual conference